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ABSTRACT
Introduction The Bowel Cancer Screening Programme in
England began operating in 2006 with the aim of full roll
out across England by December 2009. Subjects aged
60e69 are being invited to complete three guaiac faecal
occult blood tests (6 windows) every 2 years. The
programme aims to reduce mortality from colorectal
cancer by 16% in those invited for screening.
Methods All subjects eligible for screening in the
National Health Service in England are included on one
database, which is populated from National Health
Service registration data covering about 98% of the
population of England. This analysis is only of subjects
invited to participate in the first (prevalent) round of
screening.
Results By October 2008 almost 2.1 million had been
invited to participate, with tests being returned by 49.6%
of men and 54.4% of women invited. Uptake ranged
between 55e60% across the four provincial hubs which
administer the programme but was lower in the London
hub (40%). Of the 1.08 million returning tests 2.5% of
men and 1.5% of women had an abnormal test. 17 518
(10 608 M, 6910 F) underwent investigation, with 98%
having a colonoscopy as their first investigation. Cancer
(n¼1772) and higher risk adenomas (n¼6543) were
found in 11.6% and 43% of men and 7.8% and 29% of
women investigated, respectively. 71% of cancers were
‘early’ (10% polyp cancer, 32% Dukes A, 30% Dukes B)
and 77% were left-sided (29% rectal, 45% sigmoid) with
only 14% being right-sided compared with expected
figures of 67% and 24% for left and right side from UK
cancer registration.
Conclusion In this first round of screening in England
uptake and fecal occult blood test positivity was in line
with that from the pilot and the original European trials.
Although there was the expected improvement in cancer
stage at diagnosis, the proportion with left-sided cancers
was higher than expected.
INTRODUCTION
Bowel (colorectal) cancer is the cause of 16 000
deaths a year in the UK and is second only to lung
cancer as the leading cause of death from cancer in
both the UK and in Europe.1 2 Although the results
of treatment have shown a gradual improvement
over the past 30 years, 5-year survival is still only
around 50% in the UK and appears to be signiﬁ-
cantly lower than in other comparable countries.3 4
Randomised trials have shown that screening for
bowel cancer using guaiac-based faecal occult blood
tests (gFOBts) can reduce mortality by 16% in
people offered screening and 25% in those accepting
it.5 6 Economic analyses also suggest that screening
will be suitably cost-effective with a cost per
quality-adjusted life-year gained of < £3000 for
gFOBt screening.7 As a consequence many
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Significance of this study
What is already known about this subject?
< Randomised trials of colorectal (bowel) cancer
screening have indicated that a biennial guaiac-
based faecal occult blood test has the potential
to reduce colorectal cancer mortality by about
25% in those accepting screening and by 16% in
those offered screening.
< In the UK trials and pilot studies uptake was
between 50% and 60%.
< Factors such as age, ethnic background,
deprivation and gender are known to influence
uptake.
What are the new findings?
< Overall uptake in this first round of screening
was 55e60% in the provinces in keeping with
previous studies but was much lower in the
London area at only 40%.
< Uptake of the offer of colonoscopy in those with
an abnormal test was high but only 83% of
those with abnormal tests underwent
colonoscopy.
< Early cancer (Dukes A or B) was found in 70% of
those with cancer.
< The proportion of screen-detected cancers that
were found in the right colon was lower than
expected.
How might these impact on clinical practice
in the foreseeable future?
< If these early results are maintained the Bowel
Cancer Screening Programme will achieve the
intended 16% reduction in overall bowel cancer
mortality.
< Different screening strategies may be required
to effectively screen for right-sided bowel
cancer.
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countries have or are introducing bowel cancer screening
programmes.8 9 In April 2006 the Department of Health in
England agreed funding for a national programme of biennial
gFOBt screening of 60e69 year olds. Roll out of the programme
started in July 2006 and was complete by January 2010.
This paper reports on the uptake and early outcomes of the
ﬁrst million people screened.
METHODS
Identification of population invited for screening
The Bowel Cancer Screening System (BCSS) uses the 82 English
NHAIS (National Health Application and Infrastructure
Services) systems as its source of demographic information.
Software on these NHAIS systems identiﬁes eligible men and
women resident in England who are within screening age range
and registered with a GP practice. Demographic changes to these
people are updated daily.
The screening process
Starting from age 60 all subjects identiﬁed for screening are sent
an invitation to participate around the time of their birthday
and every 2 years thereafter until the age of 70 is reached.
Included with the invitation letter is an information leaﬂet
about bowel cancer and the screening process. A second letter
containing the FOBt kit and cardboard spatulas follows
1e2 weeks later with instructions for collecting the samples and
a prepaid ‘postage safe’ return envelope. The gFOBT used was
identical to that used in the pilot (Hemascreen; Immunostics,
New Jersey, USA). Each kit contains six windows and subjects
are asked to collect two small faecal samples from each of three
stools onto the windows. Subjects are not asked to make any
dietary restrictions before collecting their samples as such
restrictions might have an adverse effect on uptake and have not
been clearly shown to reduce the false-positive rate10.
Subjects are asked to return test kits within 14 days of the
ﬁrst sample being collected. Kits are dispatched by, and returned
to, one of ﬁve testing laboratories (referred to as hubs), each one
covering a large region of England as shown in ﬁgure 1. Subjects
returning kits in which ﬁve or six windows test positive are
deemed abnormal and are immediately referred to a nurse-run
clinic (specialist screening practitioner (SSP) clinic) at their local
screening centre (ﬁgure 2). Subjects returning kits with 1e4
windows testing positive are invited to repeat the test. If on the
second test any window tests positive then that too is deemed
abnormal and the subject is referred to the SSP clinic. If a second
test is negative subjects are invited to do a third test. If all six
windows are negative again then the subject is discharged from
that round of screening but if any window is positive then that
subject is also referred to the SSP clinic.
Subjects returning test kits in which all six windows test
negative on either the ﬁrst kit or on a subsequent kit are deemed
normal. They are discharged from that screening round to be re-
invited in 2 years provided they are still in the screening age
range, which was 60e69 years at the time of this analysis.
Subjects with abnormal tests are advised of their test result by
ﬁrst-class post with an offer of an appointment at an SSP clinic
within 14 days. These take place at one of a large number of sites
operated by 58 designated screening centres. During the clinic
consultation, the SSP explains the test result and that further
investigation with colonoscopy is needed to reach a diagnosis.
The risks, beneﬁts and nature of the colonoscopy procedure are
explained and a health assessment completed. If the patient
wishes to proceed, an appointment is made within 2 weeks and
the bowel preparation is provided with detailed explanation. In
<3% of FOB-positive subjects a colonoscopy is deemed not to be
appropriate as the ﬁrst investigation and a CTcolonoscopy (2%),
CTscan (0.4%) or barium enema (0.3%) is the ﬁrst investigation
performed.
All colonoscopies are undertaken at Joint Advisory Group on
GI endoscopy (http://www.thejag.org.uk/) accredited screening
centres by screening-accredited screening colonoscopists, who
have passed a formal assessment comprising 12 month personal
colonoscopy audit, multiple choice questionnaire and performed
two directly observed colonoscopies assessed independently by
two screening examiners.11 12 Ongoing quality assurance
includes assessment of caecal intubation rate, adenoma detec-
tion rate, polyp retrieval rate, colonoscopy withdrawal time,
comfort score and complications. Screening colonoscopies are
allocated 45 min time slots. An SSP accompanies the patient
during the procedure and records a detailed dataset onto the
single national BCSS database.
Patients are given the results of colonoscopy by the SSP before
they leave the department. Where nothing abnormal has been
found, the patient is discharged from that round of screening
and informed that they will be invited again for screening in
2 years’ time (provided that they are still within the eligible age
range). Where one or more polyps have been removed, the
patient is offered an appointment at an SSP follow-up clinic in
the next week. Adenoma surveillance is based on the current
British Society of Gastroenterology (BSG) guidelines.13 If
patients with adenomas are categorised as intermediate or high
risk, they enter the screening surveillance programme. This
surveillance programme is part of the BCSP and surveillance
colonoscopies are scheduled and performed by the screening
centre. Such patients are sent no further invitations to take part
in further FOB testing rounds until they leave surveillance. If
patients with adenomas are categorised as low risk, they do not
enter the screening surveillance programme, but are discharged
from that round of screening and informed that they will be
invited again for screening in 2 years’ time (provided that they
are still within the eligible age range). If a cancer is found, the
patient’s care is taken over by the hospital’s multidisciplinary
team for the management of colorectal cancer.
Figure 1 Areas of England covered by five regional Bowel Cancer
Screening Programme hubs.
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Data on adverse events associated with the screening
programme are recorded separately on a standard form which is
sent electronically to the regional quality assurance reference
centre and national ofﬁce as well as being recorded on the
screened subject’s record. Adverse event records maybe
submitted by the hubs or screening centres.
BCSS database
The BCSS is part of the ‘Open Exeter ’ suite of applications. The
‘engine’ of BCSS itself is an Oracle database. All of the system
logic and processing is performed in Oracle which provides the
results to the Java front end for display to the user. As of
October 2010 there were 1126 BCSS user accounts, of which
50% had been active in the previous 30 days. Since the imple-
mentation of BCSS in June 2006 to October 2010 there have
been 11 major software updates. Currently the BCSS database
size is 280 GB and includes the demographics for 11.2 million
people within the screening age range (currently 59e74+), their
episode history, the results of their FOBT tests and diagnostic
tests and histology information.
The main analyses are based on records downloaded from the
database in October 2008 after almost 2.1 million invitations
while the analysis of uptake of screening by socioeconomic
deprivation and hub is based on a later download performed in
January 2009 after 2.6 million invitations. This analysis is based
on uptake rates for the smallest geographical unit that is
routinely recorded by the BCSPdnamely, postcode sector.
Postcode sectors are deﬁned by the ﬁrst inward digit of the
postcode (the UK equivalent of a zip code) and contain an
average of 3000 addresses. Data from 7040 postcode sectors were
included (over 85% of the total); with an average of 378 invi-
tations per sector. We excluded 1128 postcode sectors for which
we could not retrieve census data on ethnic diversity.14 A
composite indicator of socioeconomic deprivation for each
postcode sector was derived using the Index of Multiple Depri-
vation (IMD) from 2007, which uses census-derived indicators of
income, education, employment, environment, health and
housing at small-area level to generate a scale from 0 (least
deprived) to 80 (most deprived).15 We used continuous measures
of IMD scores and compared adjusted uptake across quintiles of
the national distributions for descriptive purposes. Data were
stratiﬁed by gender, age group (60e65 years vs 66e69 years) and
screening hub.
Definitions
The following terms are deﬁned as:
Uptake (%)dSubjects returning 1+ kits/subjects invited (sent
invitation (S1) letter);
Positivity (%)dSubjects with positive gFOBt offered SSP
appointment/subjects returning any kits;
Attendance for investigation (%)dSubjects (patients) attending
for investigation/subjects offered SSP appointment;
Subjects with high risk adenomasdFive or more adenomas or
three or more with at least 1 $1 cm diameter;
Intermediate risk adenomasdThree or four small (<1 cm
diameter) adenomas or one adenoma $1 cm diameter;
Low risk adenomasdOne or two adenomas <1 cm diameter.
RESULTS
By October 2008 the screening programme had been rolled out
to 99 primary care trusts, and screening colonoscopy was being
performed in 36 screening centres across England (ﬁgure 3).
Almost 2.1 million 60e69 year olds had been sent invitations to
be screened and 52.0% had returned gFOBt kits, 49.6% (510 864)
of men invited and 54.4% (568 429) of the women invited.
Uptake, positivity and attendance for investigation
Table 1 shows uptake, positivity and investigation attendance
according to health authority area. While overall uptake was
4.8% higher in women (c2 ¼1494, p<0.00001), this difference
was greater in London and in the south of England at over 6%
and lowest in the North East at only 1.4%.
When the populations invited were stratiﬁed according to
socioeconomic indices (IMD quintiles) and by screening hub as
shown in ﬁgure 4 uptake was as expected highest in the least
deprived areas, being 61.4% overall and lowest in the most
deprived areas at 41.7% overall. However, there was striking
variation in uptake between hubs within IMD quintiles with
66.6% of the population in the lowest IMD quintile of the
North-Eastern hub returning their kits compared with only
51.6% in the same IMD quintile of the London hub. Similarly, in
areas with the highest deprivation, uptake ranged from only
33% in London to 47.6% in the North East. Indeed for every
IMD quintile, uptake was highest in areas covered by the North-
Eastern hub and lowest in the London area.
The proportion of subjects returning kits with positive
(abnormal) test results was 2.0% and was higher in men (2.5%)
Figure 2 Bowel Cancer Screening
Programme screening pathway. FOBT,
faecal occult blood test.
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than women (1.5%) (c2¼1445, p<0.00001). This difference was
of similar magnitude across all areas.
Of the 21 106 with positive (abnormal) test results, 94% went
on to attend an SSP clinic, with 6% not attending despite
reminders. The proportions subsequently undergoing investiga-
tion (83%) were the same in men and women. Of those
attending the SSP clinic, investigation was thought to be not
necessary or not appropriate in 7.6% and 3.7% either declined
the offer of investigation or failed to attend.
Findings after investigation
A total of 17 518 subjects with abnormal gFOBts attended for
investigation. For 98.1% (17 192) the ﬁrst investigation
performed was a colonoscopy and the remaining few had either
Figure 3 Extent of roll out of Bowel
Cancer Screening Programme by
primary care trusts in October 2008.
Table 1 Uptake and positivity by numbers invited, strategic health authority area and gender (after first 2 million invitations)
Strategic health
authority
Men Women
Invited
Kit
returned
Uptake
(%)
Abnormal
result %
Attended for
investigation % Invited
Kit
returned
Uptake
(%)
Abnormal
result %
Attended for
investigation %
North East 101 726 53 140 52.2 1271 2.4 1111 87 104 669 56 098 53.6 701 1.2 620 88
Yorkshire and the Humber 85 441 45 147 52.8 988 2.2 809 82 87 132 50 177 57.6 588 1.2 499 85
North West 174 264 85 506 49.1 2515 2.9 2141 85 178 708 93 521 52.3 1531 1.6 1272 83
West Midlands 122 242 63 227 51.7 1590 2.5 1288 81 123 609 69 744 56.4 1057 1.5 897 85
East Midlands 82 115 44 057 53.7 1172 2.7 952 81 82 262 47 730 58.0 829 1.7 649 78
East of England 105 422 58 493 55.5 1406 2.4 1240 88 107 488 66 353 61.7 958 1.4 829 87
London 194 564 71 620 36.8 2052 2.9 1595 78 194 138 83 502 43.0 1531 1.8 1209 79
South Central 22 466 10 430 46.4 248 2.4 183 74 22 136 11 813 53.4 160 1.4 123 77
South East Coast 56 363 31 387 55.7 609 1.9 515 85 58 817 36 513 62.1 389 1.1 309 79
South West 84 708 47 137 55.6 925 2.0 774 84 85 837 52 978 61.7 586 1.1 503 86
Total 1 029 311 510 864 49.6 12 776 2.5 10 608 83 1 044 796 568 429 54.4 8330 1.5 6910 83
1442 Gut 2012;61:1439–1446. doi:10.1136/gutjnl-2011-300843
Colon
 group.bmj.com on March 14, 2014 - Published by gut.bmj.comDownloaded from 
CT colography (1.2%), a barium enema (0.4%) or an abdominal
CT scan (0.3%). A further 943 colonoscopies were performed
later in the initial diagnostic process (tables 2 and 3).
The outcome of these investigations was not available on
BCSS for 1020 (5.8%). One thousand seven hundred and
seventy-two subjects were recorded as having a colorectal cancer
(10.1%) with the proportion being higher in men (11.6%) than
in women (7.8%) (c2¼53, p<0.0001). A further 12% of men
and 6.2% of women investigated were found to have colorectal
adenomatous polyps deﬁned as high risk and therefore invited to
have another colonoscopy in 1 year as recommended by the BSG
guidelines. An additional 19.3% of men and 14.6% of women
had polyps deﬁned as intermediate risk for which a repeat
colonoscopy is offered in 3-years’ time. Thus advanced colorectal
neoplasia (all cancers and adenomas classiﬁed as high or inter-
mediate risk) for which further treatment or investigation
was required was present in 43% of men and 29% of women
investigated.
In 11.5% (2014) of those investigated other abnormalities
were recorded as being present. Most commonly this was
diverticular disease being the only ﬁnding in 33% and being
present in association with other conditions in another 15%.
Ulcerative colitis was found in a further 15% and was recorded
as being ‘active’ in 5%. Other conditions less commonly recorded
were angiodysplasia (4.5%), Crohn’s disease (3.2%), solitary
rectal ulcer syndrome (2.0%) and radiation proctitis (1.8%).
Haemorrhoids were recorded as the only ﬁnding in 15%.
Cancer by site and stage
Table 4 shows the site distribution for 1716 of the 1772 colo-
rectal cancers detected; no site data was available on BCSS for 56
cancers. In 28.7% the cancer was recorded as being in the rectum
or rectosigmoid colon and overall 77.3% were recorded as being
left-sided colorectal cancers while only 14.3% were recorded as
being in the right colon. As expected right-sided cancer was more
commonly found in women (19.2%) than in men (12.2%) and
conversely rectal cancer was less common in women (20.3%)
than men (28.5%) (c2¼10.3, p¼0.0014)
Cancer staging data were missing for 11.2% (198/1772).
Table 5 shows the Dukes stage for the remaining 1574. A total of
71.3% of the cancers were polyp cancers or Dukes A or B and
so potentially curable which can be compared with the 72%
found with the same Dukes stage in the English pilot. Stage
distribution was similar in men and women (tables 4 and 5).
Figure 4 Uptake of faecal occult
blood test screening (%) by quintile of
Index of Multiple Deprivation (IMD)
score within each Bowel Cancer
Screening Programme hub
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Table 2 Diagnostic test results after investigation of 17 518 FOB positives after first 2 million invitations
Polyps
Missing Cancer Normal Low risk Intermediate High risk Other Total
Men 682 1230 2576 1736 2043 1293 1048 10 608
6.4% 11.6% 24.3% 16.4% 19.3% 12.2% 9.9% 100.0%
Women 338 542 2622 1007 1007 428 966 6910
4.9% 7.8% 37.9% 14.6% 14.6% 6.2% 14.0% 100.0%
Total 1020 1772 5198 2743 3050 1721 2014 17 518
5.8% 10.1% 29.7% 15.7% 17.4% 9.8% 11.5% 100.0%
FOB, faecal occult blood; VES, ????.
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Adverse events
The most commonly reported serious adverse event was bleeding
following polypectomy, for which there were 42 reports. Inmany
of these reports this was managed without admission to hospital
but in at least 12 cases bleedingwas deemed sufﬁciently serious to
warrant admission. Colonic perforations were reported after 17
colonoscopies, including one patient who needed an emergency
right hemicolectomy 12 days after screening colonoscopy; none of
these patients died. Post-colonoscopy abdominal pain was
reported as a serious adverse event on 14 occasions and in ﬁve this
resulted in an unplanned hospital admission. One patient had
a ruptured spleen after colonoscopy and another developed fever
and reported passing blue-coloured urine, which resolved within
10 h of the colonoscopy. There were a further four reports of
unplanned admissions on account of a patient being unwell after
colonoscopy.
Six deaths were reported to the National Ofﬁce. None of the
deaths reported were a direct consequence of the screening
process. Four of the deaths occurred after colectomies for screen-
detected cancers and two appeared to be unconnected with the
screening programme (one sudden death 24 days after
a screening colonoscopy and one head injury after falling
downstairs 19 days after a screening colonoscopy).
DISCUSSION
The evidence from the randomised trials of gFOBt screening
suggests that a 16% reduction in colorectal cancer mortality
should be achievable in a national programme. However,
the trials were performed by dedicated teams working with
relatively small populations. It is therefore important to
examine whether the early outcomes of the BCSP in England are
in keeping with expectations from the trials and pilot studies.
Reassuringly the overall uptake of the offer of screening across
England was 52%, with uptake outside London ranging between
55% and 60% compared with 40% in London.16 These ﬁgures are
similar to those found in both the Nottingham trial (55% in
60e69 year olds for ﬁrst invitations) in the 1980s and that
obtained in the English pilot in 2000 (57%).17 18 That the uptake
is not higher than that obtained in the Nottingham trial
20 years ago might be regarded as disappointing but in the trial
the invitation letters were sent by the subject’s general practi-
tioner and a general practitioner ’s endorsement has been found
to increase uptake.19 Similarly, the gender difference in uptake is
no surprise, although recent unpublished data suggest that this
diminishes in those over age 70 who are now being invited.
What was unexpected was the degree of difference in uptake
by region. While uptake was generally lower in areas with
greater deprivation, uptake in the North-East region was 3e5%
higher for each quintile of IMD score as shown in ﬁgure 4. In
contrast uptake was substantially lower throughout the London
region for each IMD quintile. The explanations for the lower
uptake remain to be established but may involve problems with
undelivered mail, the greater ethnic mix, large immigrant
population and greater use of private healthcare in the London
Table 3 Yield of cancer and all advanced neoplasia by numbers invited, strategic health authority area and gender after first 2 million invitations
Strategic health
authority
Men Women
Invited
Attended for
investigation Cancer %
Advanced
neoplasia* % Invited
Attended for
investigation Cancer %
Advanced
neoplasia* %
North East 10 1726 1111 132 11.9 474 43 104 669 620 48 7.7 183 30
Yorkshire and the Humber 85 441 809 102 12.6 329 41 87 132 499 46 9.2 162 32
North West 174 264 2141 257 12 956 45 178 708 1272 90 7.1 369 29
West Midlands 122 242 1288 147 11.4 560 43 123 609 897 67 7.5 230 26
East Midlands 82 115 952 103 10.8 392 41 82 262 649 50 7.7 180 28
East of England 105 422 1240 152 12.3 553 45 107 488 829 61 7.4 241 29
London 194 564 1595 156 9.8 626 39 194 138 1209 95 7.9 323 27
South Central 22 466 183 15 8.2 68 37 22 136 123 10 8.1 25 20
South East Coast 56 363 515 63 12.2 237 46 58 817 309 33 10.7 99 32
South West 84 708 774 103 13.3 371 48 85 837 503 42 8.3 165 33
Total 1 029 311 10 608 1230 11.6 4566 43 104 4796 6910 542 7.8 1977 29
*Advanced neoplasia includes all cancer and adenomatous polyps classed as high and intermediate risk.
Table 4 Site distribution of 1730 screen detected cancers
*No site coded for 37 cancers and three coded as anal and two as ileal.
1444 Gut 2012;61:1439–1446. doi:10.1136/gutjnl-2011-300843
Colon
 group.bmj.com on March 14, 2014 - Published by gut.bmj.comDownloaded from 
area. It is notable that low uptake is seen in the breast and the
cervical cancer screening programmes in London.20e22 Uptake
has been analysed in more detail elsewhere.16 23
Overall positivity at 2.0% was identical to that found in the
pilot for 60e69 year olds and marginally lower than the 2.1%
ﬁgure for the Nottingham trial.17 Positivity was 67% higher in
men than women and also higher in areas with greater depri-
vation as was also seen in the trial and in the pilot both in
England and in Scotland.24 25 While these variations in positivity
between areas may appear small, the impact on demand for
screening colonoscopies in individual screening centres is clearly
substantial. A sustained 2.5% positivity rate in an area with
average acceptance rates will result in a 25% greater demand for
colonoscopy in that screening centre compared with the
national average.
About 10% of people attending for colonoscopy were found to
have cancer, a ﬁgure very much in line with the pilot and with
the Nottingham trial, as was the higher rate in men. Numbers
are not large enough yet to reliably analyse regional patterns.
Perhaps the most unexpected ﬁnding was the proportion of
left-sided cancers which at 77% is substantially higher than the
66% found in non-screen detected colorectal cancer (CRC).2 In
comparison, of the 236 screen-detected cancers in the
Nottingham trial,74% were recorded as being in the rectum and
sigmoid colon while in the pilot the proportion that were left
sided was not reported.17
Whether this increase is a consequence of prevalence round
screening or a general consequence of CRC screening is not
clear. Several recent studies of colonoscopic CRC screening have
highlighted the ineffectiveness of such screening in protecting
from right-sided CRC and raised the possibility that the biology
of right-sided CRC may be more aggressive and hence less
amenable to detection by screening.26e28 While in some of these
studies incomplete colonoscopies might also be a factor this
appears to be an unlikely explanation within the BCSP data as
the caecal intubation rates are carefully documented, and in the
most recent analysis of over 36 000 BCSP colonoscopies the
mean rate was 95%.29 Another possibility is that right-sided
cancers tend to produce detectable occult bleeding when they
are larger than left-sided cancers. In support of this a recent
analysis from one of the screening centres has found that those
with right-sided cancers were more likely to have had a strong
positive gFOBt (5e6 windows positive) and be at an advanced
stage (Dukes stage B, C or D) than the left-sided cancers.30
Our analysis has several strengths. First, it covers most of
England and is considerably larger than other analyses done at
this stage. Second, it is a ‘real-world’ analysis using the BCSP
data as it has been collected, thus reﬂecting the screening process
on the ground. However, as a ‘real-world’ analysis we have had
to accept the limitations of the data available, including some
missing data for important variables such as cancer stage and
outcome of investigations. For some missing data it was possible
for screening centre staff to retrieve records and update the BCSS
records but this analysis has highlighted in particular the need to
ensure that the staging data are collected with the pathology
data.
There were some other limitations. Perhaps the most impor-
tant is that this was an analysis of the prevalent screening
round and we do not know how far the patterns described will
be maintained in subsequent rounds of screening. The higher
than expected proportion of left-sided cancers is possibly
a reﬂection of prevalent round screening. Another limitation
was the reliance on area-level statistics for socioeconomic
deprivation. Associations observed in area-based analyses are
likely to underestimate individual effects, so the true extent of
disparities may be higher. In some areas data were missing for
key variables such as ﬁndings from investigation and cancer
stage. We are also limited in making some comparisons with
results from other screening programmes as the classiﬁcation
of the malignancy risk for adenomas found at colonoscopy is
that of the BSG guidelines.13 This classiﬁcation ignores histo-
logical features such as villosity and dysplasia as histological
subtyping of adenomas is subjective and the reproducibility has
been found to be poor. Surveillance guidelines of other nations
vary and this makes direct comparison with other studies
difﬁcult.
These early results indicate that the BCSP in England is on
track to match the 16% reduction in CRC mortality found in the
randomised trials of gFOBt screening.5 6 It is encouraging also
that uptake outside London was generally good and quite high
by international standards. The intention is to replace the
gFOBt with a faecal immunochemical test (FIT) in the next few
years and based on the Dutch experience using a single FITwe
might expect a 25% increase in uptake and up to a doubling of
the cancer detection rate.31 However moving to a FIT will
require a substantial increase in colonoscopy capacity.
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